Consensus H. Lundbeck A/S

Stocks

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 15/06/2026 pm IST			5-day change	1st Jan Change
43.24 ^DKK	-1.05%		+0.05%	+0.19%

15/06	H. Lundbeck A/S Presents Preliminary Phase II Part A Data for Asedebart in Cushing's Disease	CI
05/06	H. Lundbeck A/S - Special Call

Evolution of the Average Target: H. Lundbeck A/S

Evolution of the Target Price: H. Lundbeck A/S

Changes in Analyst Recommendations: H. Lundbeck A/S

5faab0de59c0554bb38fe7.dXdyUII3XeEUqGtb7SqGJ8lfvHzLyMVHDI1KzTh05g8.EUMwactSM5VQxh45tXy3S5E8_RWNi4I9ZcIY-Fk6imUPOCYJwU8lj2TLLg~754aa0e735840e799d761df08f5eff81

Analysts' recommendations: H. Lundbeck A/S

13/05	H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation
13/05	Nordea raises Lundbeck price target to DKK 57 (55), reiterates Buy	FW
13/05	DNB Carnegie raises Lundbeck price target to DKK 54 (53), reiterates Buy	FW
28/04	SEB raises Lundbeck price target to DKK 46 (43), reiterates Hold	FW
27/04	UBS raises Lundbeck price target to DKK 44 (42), reiterates Neutral	FW
23/03	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
20/03	H Lundbeck: Markets need more proof of growth promise
05/03	Nordea Resumes Coverage of Lundbeck With Buy Rating – Too Cheap to Ignore	FW
05/03	Nordea Resumes Coverage of Lundbeck with Buy Rating and Price Target of 55 Danish Kroner	FW
02/03	Jefferies Upgrades Lundbeck to Hold (Underperform), Sets Price Target at 39 Danish Kroner	FW
17/02	Deutsche Bank Lowers Price Target for Lundbeck to 40 Danish Kroner (44), Maintains Hold Recommendation	FW
16/02	DNB Carnegie Raises Price Target for Lundbeck to 53 Danish Kroner (51), Reiterates Buy	FW
12/02	Barclays Lowers Price Target for Lundbeck to 45 Danish Kroner (from 50), Maintains Equal Weight - BN	FW
06/02	H Lundbeck: Weak 2026 outlook a turn-off for investors
05/02	Danske Bank Lowers Price Target for Lundbeck to 48 Danish Kroner (52), Reiterates Buy - BN	FW
05/02	UBS Lowers Price Target for Lundbeck to 42 Danish Kroner (46), Reiterates Neutral Rating	FW
05/02	SEB Lowers Price Target for Lundbeck to 43 Danish Kroner (from 50), Maintains Hold Recommendation	FW
29/01	DNB Carnegie Lowers Price Target for Lundbeck to 51 Danish Kroner (53), Reiterates Buy	FW
20/01	Danske Bank Lowers Price Target for Lundbeck to 52 Danish Kroner (55), Reiterates Buy - BN	FW
07/01	Barclays Lowers Price Target for Lundbeck to 50 Danish Kroner (from 53), Maintains Equal Weight - BN	FW
03/12	BNP Paribas Exane Raises Price Target for Lundbeck to 45 Danish Kroner, Reiterates Neutral Rating - BN	FW
20/11	UBS Raises Lundbeck Target Price to 46 Danish Kroner, Maintains Neutral Rating	FW
18/11	Barclays Raises Price Target for Lundbeck to 53 Danish Kroner, Reiterates Equal Weight	FW
14/11	H Lundbeck lifts guidance again as migraine and depression drugs drive growth
13/11	Kepler Cheuvreux Raises Target Price for Lundbeck to 65 Danish Kroner, Reiterates Buy	FW

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	H. LUNDBECK A/S					+8.03%
	MCKESSON CORPORATION					+20.07%
	CARDINAL HEALTH, INC.					+9.57%
	SIGMA HEALTHCARE LIMITED					+26.26%
	SHANGHAI PHARMACEUTICALS HOLDING CO., LTD					+25.83%
	HUADONG MEDICINE CO., LTD					+61.86%
	SINOPHARM GROUP CO. LTD.					+34.59%
	GALENICA AG					+2.65%
	JOINTOWN PHARMACEUTICAL GROUP CO., LTD					+23.9%
	MEDIPAL HOLDINGS CORPORATION					+10.41%
	Average					+22.32%
	Weighted average by Cap.					+19.36%